Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In this issue of Cancer Cell, Awad et al. report a phase 1b clinical trial combining a personalized vaccine NEO-PV-01 with chemotherapy and anti-PD-1 pembrolizumab in first-line metastatic non-squamous NSCLC. They demonstrate that this treatment regimen was well tolerated and induced neoantigen-specific CD4+ T cell responses with effector phenotype.

Original publication

DOI

10.1016/j.ccell.2022.08.002

Type

Journal article

Journal

Cancer cell

Publication Date

09/2022

Volume

40

Pages

903 - 905

Addresses

Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: carol.leung@ludwig.ox.ac.uk.

Keywords

Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Vaccination, Clinical Trials, Phase I as Topic